Confirmation of launch of commercial routine use of Renflexis® test Croissy-Beaubourg, January 19, 2018, 8:00 CET – THERADIAG (ISIN code: FR0004197747, Ticker: ALTER, eligible for PEA-PME equity savings plans), a company specialized in
in vitro diagnostics and theranostics, today announced that its US partner Miraca Life Sciences has changed its name to Inform Diagnostics. Within the framework of the technology licensing agreement of June 2016, Inform Diagnostics markets Theradiag monitoring tests in the LISA TRACKER® range in the United States under the name InformTX
TM for monitoring inflammatory bowel disease treatments. The InformTx
TM report is unique in that it provides clinicians with quantitative test results, historical test result data, and guidance from the most up-to-date peer-reviewed scientific literature. Testing measures the level of the specified drug as well as patient-derived antibodies to the specified drug. Inform Diagnostics uses laboratory-validated ELISA technology for InformTx
TM TDM, and testing results are reported within five days. At present, eight tests are available as part of the InformTX
TM range: Inflectra® (Infliximab‑dybb), Cimzia® (Certolizumab pegol), Stelara® (Ustekinumab), Simponi® (Golimumab), Remicade® (Infliximab), Humira® (Adalimumab), Entyvio® (Vedolizumab) and Renflexis® (Infliximab-abda). As announced in October
[1], the Renflexis® (Infliximab-abda) monitoring test is the latest kit to be offered by Inform Diagnostics in the United States. Following two months of tests, Theradiag confirms that the test is now available for routine use.
About Theradiag Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag is thus participating in the development of customized treatment, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. Theradiag notably markets the Lisa Tracker® range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. The Company is based in Marne-la-Vallée, near Paris, and has over 70 employees. For more information about Theradiag, please visit our website:
www.theradiag.com | Theradiag Investor Relations Fabienne François CFO Tel.: +33 (0)1 64 62 10 12 contact@theradiag.com | NewCap Financial Communications & Investor Relations Valentine Brouchot Tel.: +33 (0)1 44 71 94 94 theradiag@newcap.eu | Alize RP Press Relations Caroline Carmagnol Tel.: +33 (0)1 44 54 36 64 theradiag@alizerp.com |
[1] Eighth test in Theradiag’s monitoring range launched in the USA 